Amoxiclavulan 1A Pharma Uses

• Amoxiclavulan 1A Pharma indications
• Amoxiclavulan 1A Pharma description
• Amoxiclavulan 1A Pharma dosage
• Amoxiclavulan 1A Pharma interactions
• Amoxiclavulan 1A Pharma side effects
• Amoxiclavulan 1A Pharma contraindications

What is Amoxiclavulan 1A Pharma?

Amoxicillin (Amoxiclavulan 1A Pharma) is an antibiotic in a group of drugs called penicillins. Amoxicillin (Amoxiclavulan 1A Pharma) fights bacteria in the body.

Clavulanate potassium is a form of Clavulanic Acid (Amoxiclavulan 1A Pharma), which is similar to penicillin. Clavulanate potassium fights bacteria that is often resistant to penicillins and other antibiotics.

The combination of Amoxicillin (Amoxiclavulan 1A Pharma) and clavulanate potassium is used to treat many different infections caused by bacteria, such as sinusitis, pneumonia, ear infections, bronchitis, urinary tract infections, and infections of the skin.

Amoxicillin (Amoxiclavulan 1A Pharma) and clavulanate potassium may also be used for purposes not listed in this medication guide.

Amoxiclavulan 1A Pharma indications

Amoxiclavulan 1A Pharma-600 is indicated for the treatment of pediatric patients with recurrent or persistent acute otitis media due to S. pneumoniae (penicillin MICs ≤ 2 mcg/mL), H. influenzae (including β-lactamase–producing strains), or M. catarrhalis (including β-lactamase–producing strains) characterized by the following risk factors:

• antibiotic exposure for acute otitis media within the preceding 3 months, and either of the following:
  • age ≤ 2 years
  • daycare attendance

NOTE: Acute otitis media due to S. pneumoniae alone can be treated with Amoxicillin (Amoxiclavulan 1A Pharma). Amoxiclavulan 1A Pharma-600 is not indicated for the treatment of acute otitis media due to S. pneumoniae with penicillin MIC ≥ 4 mcg/mL.

Therapy may be instituted prior to obtaining the results from bacteriological studies when there is reason to believe the infection may involve both S. pneumoniae (penicillin MIC ≤ 2 mcg/mL) and the β-lactamase–producing organisms listed above.

To reduce the development of drug-resistant bacteria and maintain the effectiveness of Amoxiclavulan 1A Pharma-600 and other antibacterial drugs, Amoxiclavulan 1A Pharma-600 should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Amoxiclavulan 1A Pharma description

Each film-coated tablet contains Amoxicillin (Amoxiclavulan 1A Pharma) trihydrate equivalent to Amoxicillin (Amoxiclavulan 1A Pharma) 500 mg, and potassium clavulanate equivalent to Clavulanic Acid (Amoxiclavulan 1A Pharma) 125 mg, respectively.

Each vial contains Amoxicillin (Amoxiclavulan 1A Pharma) sodium equivalent to Amoxicillin (Amoxiclavulan 1A Pharma) 1000 mg and clavulanate potassium equivalent to Clavulanic Acid (Amoxiclavulan 1A Pharma) 200 mg, respectively.

Amoxiclavulan 1A Pharma tablets also contains the following excipients: Microcrystalline cellulose, sodium starch glycolate, anhydrous colloidal silica, povidone (K30), eudragit E 100, isopropyl alcohol, magnesium stearate, white opadryl 03B58965, PEG400, methylene chloride.

Amoxiclavulan 1A Pharma is an antibacterial combination consisting of the semi-synthetic antibiotic Amoxicillin (Amoxiclavulan 1A Pharma) and the β-lactamase inhibitor, clavulanate potassium (the potassium salt of Clavulanic Acid (Amoxiclavulan 1A Pharma)). Amoxicillin (Amoxiclavulan 1A Pharma) is an analog of ampicillin, derived from the basic penicillin nucleus, 6-aminopenicillanic acid. Its molecular formula is C₁₆H₁₉N₃0₅S3H₂0 and the molecular weight is 419.46. Chemically, Amoxicillin (Amoxiclavulan 1A Pharma) is (2S, 5R, 6R)-6-[(R)-(-)-2-Amino-2-(p-hydroxyphenyl) acetamido]-3, 3-dimethyl-7-oxo-4-1-azabicyclo[3.2.1] heptane-2-carboxylic acid trihydrate.

Amoxicillin (Amoxiclavulan 1A Pharma): Clavulanic Acid (Amoxiclavulan 1A Pharma) is produced by the fermentation of Streptomyces clavuligerus. It is a β-lactam structurally related to the penicillins and possesses the ability to inactivate a wide variety of β-lactamases by blocking the active sites of these enzymes. Clavulanic Acid (Amoxiclavulan 1A Pharma) is particularly active against the clinically important plasmid-mediated β-lactamases frequently responsible for transferred drug resistance to penicillins and cephalosporins. The clavulanate potassium molecular formula is C₈H₈KN0₅ and the molecular weight is 237.25. Chemically, clavulanate potassium is potassium (Z)-(2R, 5R)-3-(2-hydroxyethylidene)-7-oxo-4-oxa-1-azabicyclo[3.2.0]-heptane-2-carboxylate.

Amoxiclavulan 1A Pharma dosage

Tablet: Tablets should be taken immediately before a meal.

General Information: For infections caused by Amoxicillin (Amoxiclavulan 1A Pharma)-sensitive organisms, the dosage is that approved for Amoxicillin (Amoxiclavulan 1A Pharma) as the Clavulanic Acid (Amoxiclavulan 1A Pharma) component does not contribute to the therapeutic effect.

Adults: 1 or 2 Amoxiclavulan 1A Pharma 375 mg tab 8 hourly or 1 Amoxiclavulan 1A Pharma 625 mg tab 8 hourly for more severe infections and infections of the respiratory tract.

For Amoxicillin (Amoxiclavulan 1A Pharma)-resistant organisms, the dosage of Amoxiclavulan 1A Pharma tablets are as follows:

Since both Amoxiclavulan 1A Pharma 375 mg and 625 mg contain the same amount of Clavulanic Acid (Amoxiclavulan 1A Pharma) (125 mg, as the potassium salt), 2 Amoxiclavulan 1A Pharma 375 mg are not equivalent to 1 Amoxiclavulan 1A Pharma 625 mg. Therefore, 2 Amoxiclavulan 1A Pharma 375 mg should not be substituted for 1 Amoxiclavulan 1A Pharma 625 mg for treatment of more severe infections.

Renal Failure: Both Amoxicillin (Amoxiclavulan 1A Pharma) and Clavulanic Acid (Amoxiclavulan 1A Pharma) are excreted by the kidneys and the serum t_½ of each increases in patients with renal failure. Therefore, the dose may need to be reduced or the interval extended. The following schedule in the dosage is proposed:

Haemodialysis decreases serum concentrations of both Amoxicillin (Amoxiclavulan 1A Pharma) and Clavulanic Acid (Amoxiclavulan 1A Pharma) and an additional dose should be administered at the end of dialysis.

Oral Suspension:

Suspensions should be taken immediately before a meal.

Reconstitution: For reconstitution to 30 mL, add water till the mark, invert the bottle and shake well until all the powder is dispersed.

Children: 25-50 mg/kg/day of the 4 parts Amoxicillin (Amoxiclavulan 1A Pharma), 1 part Clavulanic Acid (Amoxiclavulan 1A Pharma) preparations (which corresponds to a daily dosage of the equivalent of Amoxicillin (Amoxiclavulan 1A Pharma) 20-40 mg/kg and Clavulanic Acid (Amoxiclavulan 1A Pharma) 5-10 mg/kg) to be taken in divided doses every 8 hrs at the start of a meal.

Dosage Guide:

To correspond to a dosage of 25-50 mg/kg/day.

To correspond to a dosage of 50 mg/kg/day.

IV/IM: Amoxiclavulan 1A Pharma may be administered by the IV routes.

Amoxiclavulan 1A Pharma is administered by IM or slow IV injection in doses of 500 mg every 8 hrs.

Severe Infections: 1 g every 6 hrs by slow IV injection over 3-4 min or by infusion over 30-60 min.

Children ≤10 years: 50-100 mg/kg body weight daily by injection in divided doses.

Amoxiclavulan 1A Pharma interactions

See also:
What other drugs will affect Amoxiclavulan 1A Pharma?

Probenecid decreases the renal excretion of Amoxicillin (Amoxiclavulan 1A Pharma). Concurrent use with Amoxiclavulan 1A Pharma may result in increased and prolonged blood levels of Amoxicillin (Amoxiclavulan 1A Pharma).

The concurrent administration of allopurinol and ampicillin increases the incidence of rashes in patients receiving both drugs as compared to patients receiving ampicillin alone. But it is not known whether this potentiation of ampicillin rash is due to allopurinol or the hyperuricemia present in these patients.

Amoxiclavulan 1A Pharma should not be co-administrated with disulfiram.

Prolongation of bleeding time and prothrombin time have been reported in some patients receiving Amoxiclavulan 1A Pharma. Thus, Amoxiclavulan 1A Pharma should be used with care in patients on anticoagulation therapy.

Amoxiclavulan 1A Pharma may reduce the effect of oral contraceptives and the caution should be given to patients.

Laboratory Test Interactions: Amoxiclavulan 1A Pharma results in high urine concentration. High urine concentration of ampicillin may result in false-positive reactions when testing for the presence of glucose in urine using Clinitest, Benedict or Fehling's solution.

Amoxiclavulan 1A Pharma side effects

See also:
What are the possible side effects of Amoxiclavulan 1A Pharma?

The most frequently reported adverse effects were diarrhoea, nausea, vomiting, abdominal pain, skin rashes, urticaria and erythema multiforme, vaginitis, abnormal taste, headache, dizziness, tiredness and hot flushes. The incidence and severity of adverse effects, particularly nausea and diarrhoea, increased with the higher recommended dose and can be minimised by administering the agent at the start of a meal. In addition, as these symptoms are especially related to the potassium clavulanate component, where these GI symptoms occur and a higher concentration of Amoxicillin (Amoxiclavulan 1A Pharma) is required, consideration should be given to administering the additional Amoxicillin (Amoxiclavulan 1A Pharma) separately.

Hepatitis and cholestatic jaundice have been reported with the combination of Amoxicillin (Amoxiclavulan 1A Pharma) and Clavulanic Acid (Amoxiclavulan 1A Pharma); the Clavulanic Acid (Amoxiclavulan 1A Pharma) component has been implicated. The events associated with Amoxiclavulan 1A Pharma may be severe and occur predominantly in adult or elderly patients. Signs and symptoms usually occur during or shortly after treatment, but in some cases may not become apparent until several weeks after treatment has ceased. The hepatic events are usually reversible. However, in extremely rare circumstances, death has been reported. These have almost always been cases associated with serious underlying disease or concomitant medication.

A moderate rise in aspartate transaminase and/or alanine transaminase has been noted in patients treated with Amoxiclavulan 1A Pharma, the significance of these findings is unknown.

The following adverse reactions have been reported for ampicillin class antibiotics and may occur with Amoxiclavulan 1A Pharma.

Gastrointestinal: Gastritis, stomatitis, glossitis, black hairy tongue, enterocolitis and pseudomembranous colitis. If GI reactions are evident, they may be reduced by taking Amoxiclavulan 1A Pharma at the start of a meal.

Amoxicillin (Amoxiclavulan 1A Pharma) causes hypersensitivity reactions similar to those induced by penicillin G and ampicillin, including rashes and fever. The incidence of these reaction is probably no higher than with other penicillins. Sensitivity reactions are more likely to occur in individuals who have previously demonstrated hypersensitivity to penicillins and in those with a history of allergy, asthma, hay fever or uticaria. Hypersensitivity reactions include skin rashes, urticaria, erythema multiforme, rare cases of Stevens-Johnson syndrome and less frequently exfoliative dermatitis and toxic epidermal necrolysis have been reported. Whenever such reactions occur, Amoxiclavulan 1A Pharma should be discontinued. Serious and occasional fatal hypersensitivity (anaphylactic) reactions and angioneurotic oedema can occur with oral penicillin.

Haematopoietic and Lymphatic: Anaemia, thrombocytopenia, thrombocytopenic purpura, eosinophilia, leucopenia and agranulocytosis have been reported during therapy with penicillins. These reactions are usually reversible on discontinuation of therapy and are believed to be hypersensitivity phenomena. A slight thrombocytosis was noted in patients treated with Amoxiclavulan 1A Pharma. Prolongation of bleeding time and prothrombin time have also been reported less frequently.

Amoxicillin (Amoxiclavulan 1A Pharma) alone or in combination with Clavulanic Acid (Amoxiclavulan 1A Pharma) has been associated with acute hepatic dysfunction. The incidence rate (95% confidence intervals) were 1.7 (1.1-2.7) (Amoxicillin (Amoxiclavulan 1A Pharma)-Clavulanic Acid (Amoxiclavulan 1A Pharma)) and 0.3 (0.2-0.5)/10,000 prescriptions (Amoxicillin (Amoxiclavulan 1A Pharma) alone). Risks were increased in patients receiving >1 course and in older recipients.

Central Nervous System: Reversible hyperactivity, agitation, anxiety, insomnia, confusion, behavioural changes and/or dizziness have also been reported. Depression, seizures or hallucinations.

Amoxiclavulan 1A Pharma contraindications

Hypersensitivity to the Amoxicillin (Amoxiclavulan 1A Pharma)/clavulanate potassium to any of the penicillins or to any of the excipients of Amoxiclavulan 1A Pharma.

History of a severe immediate hypersensitivity reaction (eg, anaphylaxis) to another β-lactam agent (eg, a cephalosporin, carbapenem or monobactam).

History of cholestatic jaundice/hepatic dysfunction due to Amoxiclavulan 1A Pharma.

Active ingredient matches for Amoxiclavulan 1A Pharma:

Amoxicillin/Clavulanic Acid in Austria.

List of Amoxiclavulan 1A Pharma substitutes (brand and generic names)	Sort by popularity
Unit description / dosage (Manufacturer)	Price, USD
AmoxiClavulan (Austria)
Amoxiclin-CL (Peru)
Amoxiclin-CL 12h (Peru)
Amoxicomp (Austria)
Amoxicomp Genericon (Austria)
Amoxicomp Genericon 1g (Austria)
Amoxicure-C (India)
Amoxicure-C Amoxicillin trihydrate 500 mg, Clavulanate potassium 125 mg. TAB / 6 (Balsons (Best Cure))	$ 1.08
6's (Balsons (Best Cure))	$ 1.08
AMOXICURE-C tab 6's (Balsons (Best Cure))	$ 1.08
Amoxidal Plus (Paraguay, Uruguay)
Amoxidin CL (Peru)
Amoxidura plus (Germany)
Tablet, Film-Coated; Oral; Amoxicillin Trihydrate 500 mg; Clavulanic Acid / Clavulanate Potassium 125 mg (Merck dura)
Tablet, Film-Coated; Oral; Amoxicillin Trihydrate 875 mg; Clavulanic Acid / Clavulanate Potassium 125 mg (Merck dura)
Amoxigard (Bulgaria)
Amoxigrand Compuesto (Argentina)
Amoxiland Plus (Paraguay)
Amoxilanic (Egypt)
Amoxilanico (Peru)
Amoxilanico Duo (Peru)
Amoxilite Plus (Pakistan)
Amoxillat-Clav (Germany)
Tablet, Film-Coated; Oral; Amoxicillin Trihydrate 500 mg; Clavulanic Acid / Clavulanate Potassium 125 mg (Azupharma)
Tablet, Film-Coated; Oral; Amoxicillin Trihydrate 875 mg; Clavulanic Acid / Clavulanate Potassium 125 mg (Azupharma)
AMOXIMENTIN
AMOXIMENTIN 500MG/125MG TABLET 1 strip / 6 tablets each (PCI Pharmaceuticals)	$ 0.83
Amoximentin 500 mg/125 mg Tablet (PCI Pharmaceuticals)	$ 0.14
Amoxin Comp (Finland)
Amoxiplus (Romania)
Amoxiplus 1.2g (Serbia)
Amoxiplus ratiopharm (Austria)
Amoxiplus ratiopharm 156,25 mg/5 ml (Austria)
Amoxiplus ratiopharm 1g (Austria)
Amoxiplus ratiopharm 625 mg (Austria)
Amoxiplus ratiopharm forte (Austria)
Amoxiplus ratiopharm forte 312,5 mg/5 ml (Austria)
Amoxistad plus (Austria)
Amoxistad plus 875 mg/125 mg (Austria)
Amoxitenk (Argentina)
Amoxitenk Plus (Argentina)
Amoxitenk Plus Pediátrica (Argentina)
AMOXRAG (India)
1's (Auriga)	$ 1.45
6's (Auriga)	$ 2.17
Amoxrag Amoxicillin 1 g, clavulanicacid 0.2 g. POWD / 1 (Auriga)	$ 1.45
Amoxrag Amoxicillin 250 mg, clavulanicacid 125 mg. TAB / 6 (Auriga)	$ 1.59
See 7042 substitutes for Amoxiclavulan 1A Pharma

References

1. DailyMed. "AMOXICILLIN; CLAVULANATE POTASSIUM: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
2. PubChem. "CLAVULANIC ACID". https://pubchem.ncbi.nlm.nih.gov/com... (accessed September 17, 2018).
3. PubChem. "amoxicillin". https://pubchem.ncbi.nlm.nih.gov/com... (accessed September 17, 2018).

Reviews

The results of a survey conducted on ndrugs.com for Amoxiclavulan 1A Pharma are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Amoxiclavulan 1A Pharma. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.

User reports

Consumer reviews

There are no reviews yet. Be the first to write one!

Your name:  Email:  Spam protection:  < Type 9 here

Information checked by Dr. Sachin Kumar, MD Pharmacology